However, increased CD26 expression within tumors harbors another, potentially favorable opportunity for an immune-modulating treatment: an increased density of CD26 within the tumor consequently leads to the increased enzymatic cleavage of tumor-relevant chemokines. The gene discussed is DPP4; the disease is neoplasm.